Q&A: FDA approval of dupilumab for eosinophilic esophagitis a ‘victory for rare diseases’

The FDA has approved the use of dupilumab for treating eosinophilic esophagitis in adults and children aged 12 years and older, making it the first drug in the U.S. specifically indicated for this condition.During the first half of the pivotal Phase 3 trial that served as the basis for the approval, 60% of patients on dupilumab (Dupixent; Sanofi, Regeneron) achieved a reduction of their eosinophil count to a normal range. Patients also showed a 22-point average improvement in their Dysphagia Symptom Questionnaire (DSQ) score.In the second half of the trial, 59% of patients on the drugRead More

Related Articles